Overview

Efficacy of a Standardized Centella Asiatica Extract in Patients With Temporomandibular Disorder

Status:
COMPLETED
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test analgesic effect of ECa 233 in subjects with TMD. The main questions it aims to answer are: * Can ECa 233 reduce pain intensity score in subjects with acute TMD? * Can ECa 233 increase jaw functional movements in subjects with acute TMD? Participants will be separated into four groups, including placebo, ibuprofen, low-dosed Eca and high-dosed Eca groups.
Phase:
PHASE2
Details
Lead Sponsor:
Chulalongkorn University
Treatments:
Anti-Inflammatory Agents, Non-Steroidal
ECa 233 extract
Ibuprofen
Lactose